Paper Details

  1. Home
  2. Paper Details

Population Pharmacokinetics of Rolapitant in Patients With Chemotherapy-Induced Nausea and Vomiting.

Author: KansraVikram, WangJing, WangXiaodong, ZhangZhi-Yi

Clinical Trial, Phase IIA Phase II trial is a trial that further evaluates the efficacy and safety of a new drug or treatment, whose safety has been confirmed to some extent in a Phase I trial, in a small number of patients.
Clinical Trial, Phase IIIA Phase III trial is a trial that further rigorously verifies the efficacy and safety of a new drug or treatment, whose efficacy and safety have been confirmed in a Phase II trial, in a large number of patients, and evaluates whether it is superior to existing treatments.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

This study examined the population pharmacokinetics of rolapitant and its metabolite M19 in 482 patients receiving the drug for prevention of chemotherapy-induced nausea and vomiting. The model showed that weight positively correlated with drug distribution volume. No dose adjustments were recommended for other patient variables.
Paper Details　
Original Abstract of the Article :
Population pharmacokinetics of rolapitant and its active metabolite M19 were studied in 482 patients receiving this neurokinin-1 receptor antagonist in combination with a 5-hydroxytryptamine-3 receptor antagonist and dexamethasone for prevention of chemotherapy-induced nausea and vomiting (CINV). Pa...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1002/cpdd.733

データ提供：米国国立医学図書館（NLM）

Rolapitant: A Steady Caravan in the Desert of Chemotherapy-Induced Nausea

Chemotherapy, a powerful weapon in the fight against cancer, often comes with an unwelcome side effect: nausea and vomiting. Imagine a caravan of camels carrying precious medicines across a desert, but the journey is fraught with discomfort and unpleasant side effects. This research focuses on rolapitant, a medication designed to combat chemotherapy-induced nausea and vomiting (CINV), and explores its pharmacokinetic properties. It analyzes the way rolapitant is absorbed, distributed, metabolized, and eliminated in the body, seeking to optimize its effectiveness and minimize side effects.

A Reliable Caravan: Ensuring a Smooth Journey

The study found that rolapitant's pharmacokinetic profile is characterized by a two-compartment model, suggesting a relatively predictable and reliable pattern of absorption, distribution, and elimination. The researchers determined the typical values for various pharmacokinetic parameters, including clearance and volume of distribution. They also found that weight was positively correlated with the volume of distribution, indicating that higher doses might be needed for heavier patients.

Navigating the Desert with Confidence: A Dose for Every Camel

This research provides valuable insights into the pharmacokinetic behavior of rolapitant, helping to optimize its use in preventing CINV. The study demonstrates that no dose adjustments are necessary based on most patient variables, supporting the use of a standard dose for most individuals. The research also suggests a potential association between rolapitant exposure and efficacy, implying that higher exposure may lead to better outcomes.

Dr. Camel's Conclusion

This research on rolapitant offers a valuable roadmap for navigating the desert of chemotherapy-induced nausea. By understanding its pharmacokinetic properties, physicians can confidently prescribe rolapitant to patients undergoing chemotherapy, helping to minimize the discomfort and improve the overall experience. Just as a seasoned caravan leader guides his camels across the desert with knowledge and precision, physicians equipped with this knowledge can provide their patients with the best possible care during their journey.

Date :
  1. Date Completed 2020-08-04
  2. Date Revised 2020-08-04
Further Info :

Pubmed ID

31418538

DOI: Digital Object Identifier

10.1002/cpdd.733

Related Literature

Article Analysis
・Effects of rolapitant
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.